

Next generation antibody drugs: pursuit of the 'high-ha

Nature Reviews Drug Discovery

17, 197-223

DOI: [10.1038/nrd.2017.227](https://doi.org/10.1038/nrd.2017.227)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of an analytical method to assess the occupational health risk of therapeutic monoclonal antibodies using LC-HRMS. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 2829-2836.	1.9	6
2	Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non- $\kappa$ Ig scaffolds. <i>Medicinal Research Reviews</i> , 2018, 38, 1837-1873.	5.0	12
3	Hyphenation of size exclusion chromatography to native ion mobility mass spectrometry for the analytical characterization of therapeutic antibodies and related products. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1086, 176-183.	1.2	69
4	Cell-surface proteomics for the identification of novel therapeutic targets in cancer. <i>Expert Review of Proteomics</i> , 2018, 15, 259-275.	1.3	51
5	An Online Four-Dimensional HIC-SEC-IM-MS Methodology for Proof-of-Concept Characterization of Antibody Drug Conjugates. <i>Analytical Chemistry</i> , 2018, 90, 1578-1586.	3.2	75
6	Site-Specific Antibody Functionalization Using Tetrazine-Styrene Cycloaddition. <i>Bioconjugate Chemistry</i> , 2018, 29, 1605-1613.	1.8	12
7	Antibody Modeling, Engineering, and Design. , 2018, , 1-8.		0
8	Characterization of Biopharmaceuticals Focusing on Antibody Therapeutics. , 2018, , .		2
9	Helminth eggs as parasitic indicators of fecal contamination in agricultural irrigation water, biosolids, soils and pastures. <i>Biomedica</i> , 2018, 38, 42.	0.3	4
10	Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3685.	1.8	32
11	Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	43
12	In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas. <i>ACS Omega</i> , 2018, 3, 14726-14731.	1.6	23
13	Bioanalytical workflow for novel scaffold protein-drug conjugates: quantitation of total Centyrin protein, conjugated Centyrin and free payload for Centyrin-drug conjugate in plasma and tissue samples using liquid chromatography-tandem mass spectrometry. <i>Bioanalysis</i> , 2018, 10, 1651-1665.	0.6	12
14	Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes. <i>Cell Reports</i> , 2018, 25, 523-535.e5.	2.9	20
15	Isotonic concentrations of excipients control the dimerization rate of a therapeutic immunoglobulin G1 antibody during refrigerated storage based on their rank order of native-state interaction. <i>Protein Science</i> , 2018, 27, 2073-2083.	3.1	5
16	Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer. <i>Bioconjugate Chemistry</i> , 2018, 29, 3817-3832.	1.8	14
17	From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 6677-6688.	3.3	27
18	Target Identification Using Chemical Probes. <i>Methods in Enzymology</i> , 2018, 610, 27-58.	0.4	9

#	ARTICLE	IF	CITATIONS
19	Targeted Intracellular Delivery of Antibodies: The State of the Art. <i>Frontiers in Pharmacology</i> , 2018, 9, 1208.	1.6	144
20	Antibody-mediated protection against Ebola virus. <i>Nature Immunology</i> , 2018, 19, 1169-1178.	7.0	127
21	Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	96
22	Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9583-9595.	2.9	19
23	A Novel Online Four-Dimensional SEC-SEC-MS Methodology for Characterization of Monoclonal Antibody Size Variants. <i>Analytical Chemistry</i> , 2018, 90, 13929-13937.	3.2	49
24	Local delivery of macromolecules to treat diseases associated with the colon. <i>Advanced Drug Delivery Reviews</i> , 2018, 136-137, 2-27.	6.6	72
25	MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. <i>Expert Review of Proteomics</i> , 2018, 15, 733-748.	1.3	27
26	Engaging with Raman Spectroscopy to Investigate Antibody Aggregation. <i>Antibodies</i> , 2018, 7, 24.	1.2	31
27	Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity. <i>Methods in Molecular Biology</i> , 2018, 1827, 381-397.	0.4	7
28	Characterization of recombinant monoclonal IgG2 antibodies using LC-MS and limited Lys-C digestion. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1092, 15-18.	1.2	6
29	New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9004-9029.	2.9	39
30	Monoclonal antibody-mediated killing of tumour cells by neutrophils. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12962.	1.7	32
31	Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding. <i>Analytical Chemistry</i> , 2018, 90, 7325-7331.	3.2	31
32	Mechanisms of protein toxicity in neurodegenerative diseases. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 3159-3180.	2.4	103
33	Native Mass Spectrometry, Ion Mobility, and Collision-Induced Unfolding for Conformational Characterization of IgG4 Monoclonal Antibodies. <i>Analytical Chemistry</i> , 2018, 90, 8865-8872.	3.2	51
34	Cytokine release syndrome. , 2018, 6, 56.		1,055
35	Characterizing various monoclonal antibodies with milder reversed phase chromatography conditions. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1096, 1-10.	1.2	25
36	Subcutaneous delivery of monoclonal antibodies: How do we get there?. <i>Journal of Controlled Release</i> , 2018, 286, 301-314.	4.8	138

#	ARTICLE	IF	CITATIONS
37	Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing $\gamma\delta$ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 814.	2.2	84
38	Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions. <i>Frontiers in Oncology</i> , 2018, 8, 152.	1.3	30
39	Recent developments with immunotherapy for hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 905-910.	1.4	89
40	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 285.	1.3	89
41	Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. <i>Human Antibodies</i> , 2018, 27, 37-51.	0.6	27
42	Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates. <i>BioDrugs</i> , 2018, 32, 465-480.	2.2	40
43	A site-specific branching poly-glutamate tag mediates intracellular protein delivery by cationic lipids. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 671-676.	1.0	2
44	Laboratory mice born to wild mice have natural microbiota and model human immune responses. <i>Science</i> , 2019, 365, .	6.0	360
45	Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery. <i>Biomaterials</i> , 2019, 219, 119373.	5.7	39
46	Proteomics for cancer drug design. <i>Expert Review of Proteomics</i> , 2019, 16, 647-664.	1.3	9
47	A Case Study to Identify the Drug Conjugation Site of a Site-Specific Antibody-Drug-Conjugate Using Middle-Down Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 2419-2429.	1.2	23
48	Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor. <i>Frontiers in Immunology</i> , 2019, 10, 1396.	2.2	13
49	Intracellular targets as source for cleaner targets for the treatment of solid tumors. <i>Biochemical Pharmacology</i> , 2019, 168, 275-284.	2.0	8
50	Deep Mining of Complex Antibody Phage Pools Generated by Cell Panning Enables Discovery of Rare Antibodies Binding New Targets and Epitopes. <i>Frontiers in Pharmacology</i> , 2019, 10, 847.	1.6	31
51	Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. <i>Frontiers in Immunology</i> , 2019, 10, 1296.	2.2	211
52	Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells. <i>MABs</i> , 2019, 11, 1254-1265.	2.6	19
53	Extended scaffold glucuronides: <i>in route</i> to the universal synthesis of <i>O</i> -aryl glucuronide prodrugs. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 6970-6974.	1.5	11
54	Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer. <i>Journal of Inorganic Biochemistry</i> , 2019, 199, 110780.	1.5	33

#	ARTICLE	IF	CITATIONS
55	T Cell-Activating Bispecific Antibodies in Cancer Therapy. <i>Journal of Immunology</i> , 2019, 203, 585-592.	0.4	55
56	Targeting Pathogenic Listeria Bacteria in Listeria Disease Using an Antibody-Enzyme Fusion. <i>Cell Metabolism</i> , 2019, 30, 689-705.e6.	7.2	66
57	Cytosolic delivery of inhibitory antibodies with cationic lipids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22132-22139.	3.3	39
58	Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models. <i>Frontiers in Immunology</i> , 2019, 10, 1602.	2.2	4
59	In Vivo Brain Delivery and Brain Deposition of Proteins with Various Sizes. <i>Molecular Pharmaceutics</i> , 2019, 16, 4878-4889.	2.3	9
60	Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics. <i>BioTechniques</i> , 2019, 67, 261-269.	0.8	10
61	Remicade (infliximab): 20 years of contributions to science and medicine. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 139-178.	3.0	78
62	Antibody-drug conjugates for cancer. <i>Lancet, The</i> , 2019, 394, 793-804.	6.3	425
63	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2019, 14, 591-601.	1.7	43
64	Proof of Concept To Achieve Infinite Selectivity for the Chromatographic Separation of Therapeutic Proteins. <i>Analytical Chemistry</i> , 2019, 91, 12954-12961.	3.2	30
65	One, if by land, and two, if by sea: bispecific antibodies join the revolution. <i>Methods</i> , 2019, 154, 1-2.	1.9	4
66	Site-specific labeling of an anti-MUC1 antibody: probing the effects of conjugation and linker chemistry on the internalization process. <i>RSC Advances</i> , 2019, 9, 1909-1917.	1.7	7
67	Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual $\beta$ -glucuronide and dipeptide triggers. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 591-607.	2.6	16
68	A brief history of antibody-based therapy. <i>Neurobiology of Disease</i> , 2019, 130, 104504.	2.1	8
69	Efficient Phage Display with Multiple Distinct Non-Canonical Amino Acids Using Orthogonal Ribosome-Mediated Genetic Code Expansion. <i>Angewandte Chemie</i> , 2019, 131, 10960-10964.	1.6	4
70	Sortase A Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody-Drug Conjugates. <i>Methods in Molecular Biology</i> , 2019, 2012, 1-13.	0.4	10
71	New drugs for old targets. <i>Hematological Oncology</i> , 2019, 37, 101-104.	0.8	2
72	Quantitative analysis of operators™ flow line in the cell culture for controlled manual operation. <i>Regenerative Therapy</i> , 2019, 12, 43-54.	1.4	3

#	ARTICLE	IF	CITATIONS
73	Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. <i>MAbs</i> , 2019, 11, 996-1011.	2.6	28
74	Efficient Phage Display with Multiple Distinct Non-Canonical Amino Acids Using Orthogonal Ribosome-Mediated Genetic Code Expansion. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 10844-10848.	7.2	41
75	Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity. <i>Cell Reports</i> , 2019, 27, 3117-3123.e5.	2.9	18
76	Optical Control of Antibody Activity by Using Photocleavable Bivalent Peptide-DNA Locks. <i>ChemBioChem</i> , 2019, 20, 2463-2466.	1.3	18
77	Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 339-359.	0.8	17
78	The Analysis of Key Factors Related to ADCs Structural Design. <i>Frontiers in Pharmacology</i> , 2019, 10, 373.	1.6	45
79	B cells engineered to express pathogen-specific antibodies protect against infection. <i>Science Immunology</i> , 2019, 4, .	5.6	87
80	Human Fcγ3 receptors compete for TGN1412 binding that determines the antibody's effector function. <i>European Journal of Immunology</i> , 2019, 49, 1117-1126.	1.6	6
81	High-Throughput Quantification of Surface Protein Internalization and Degradation. <i>ACS Chemical Biology</i> , 2019, 14, 1154-1163.	1.6	14
82	Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform. <i>MAbs</i> , 2019, 11, 666-680.	2.6	25
83	High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 81-92.	1.9	17
84	Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins. <i>ACS Chemical Biology</i> , 2019, 14, 916-924.	1.6	29
85	Bioanalytical challenges and unique considerations to support pharmacokinetic characterization of bispecific biotherapeutics. <i>Bioanalysis</i> , 2019, 11, 427-435.	0.6	10
86	HVEM network signaling in cancer. <i>Advances in Cancer Research</i> , 2019, 142, 145-186.	1.9	30
87	Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fcγ3R Interaction. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 780-787.	1.9	40
88	Fast protein sequencing of monoclonal antibody by real-time digestion on emitter during nanoelectrospray. <i>MAbs</i> , 2019, 11, 767-778.	2.6	5
89	Modifications of recombinant monoclonal antibodies in vivo. <i>Biologicals</i> , 2019, 59, 1-5.	0.5	9
90	Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis. <i>MAbs</i> , 2019, 11, 848-860.	2.6	40

#	ARTICLE	IF	CITATIONS
91	David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments. <i>Antibodies</i> , 2019, 8, 28.	1.2	136
92	Characterization of Antibody Products Obtained through Enzymatic and Nonenzymatic Glycosylation Reactions with a Glycan Oxazoline and Preparation of a Homogeneous Antibody-Drug Conjugate via Fc N-Glycan. <i>Bioconjugate Chemistry</i> , 2019, 30, 1343-1355.	1.8	30
93	Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. <i>MAbs</i> , 2019, 11, 919-929.	2.6	19
94	Discovery and characterization of CHO host cell protease-induced fragmentation of a recombinant monoclonal antibody during production process development. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1112, 1-10.	1.2	17
95	Antibodies and venom peptides: new modalities for ion channels. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 339-357.	21.5	119
96	The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?. <i>Frontiers in Pharmacology</i> , 2019, 10, 80.	1.6	49
97	<sup>89</sup> Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake. <i>Clinical Cancer Research</i> , 2019, 25, 3517-3527.	3.2	34
98	An Expanded Conformation of an Antibody Fab Region by X-Ray Scattering, Molecular Dynamics, and smFRET Identifies an Aggregation Mechanism. <i>Journal of Molecular Biology</i> , 2019, 431, 1409-1425.	2.0	19
99	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. <i>Scientific Reports</i> , 2019, 9, 2064.	1.6	53
100	Precision medicine for human cancers with Notch signaling dysregulation (Review). <i>International Journal of Molecular Medicine</i> , 2020, 45, 279-297.	1.8	105
101	Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2019, 10, 2856.	2.2	8
102	Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1443-1456.	1.7	30
103	In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR T Cell Therapy. <i>HemaSphere</i> , 2019, 3, e191.	1.2	80
104	Recent Progress in Linker Technology for Antibody-Drug Conjugates: Methods for Connection and Release. , 2019, , 93-123.		2
105	Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development. <i>Current Opinion in Biotechnology</i> , 2019, 55, 51-59.	3.3	202
106	Comprehensive characterization of monoclonal antibody by Fourier transform ion cyclotron resonance mass spectrometry. <i>MAbs</i> , 2019, 11, 106-115.	2.6	50
107	Designed and Evolved Nucleic Acid Nanotechnology: Contrast and Complementarity. <i>Bioconjugate Chemistry</i> , 2019, 30, 2-12.	1.8	4
108	Engineering an EGFR-binding Gp2 domain for increased hydrophilicity. <i>Biotechnology and Bioengineering</i> , 2019, 116, 526-535.	1.7	3

#	ARTICLE	IF	CITATIONS
109	Development, Optimization, and Structural Characterization of an Efficient Peptide-Based Photoaffinity Cross-Linking Reaction for Generation of Homogeneous Conjugates from Wild-Type Antibodies. <i>Bioconjugate Chemistry</i> , 2019, 30, 148-160.	1.8	17
110	Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 241-255.	12.5	56
111	Oligoclonal selection of nanobodies targeting vascular endothelial growth factor. <i>Journal of Immunotoxicology</i> , 2019, 16, 34-42.	0.9	15
112	Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies. <i>Clinical and Translational Science</i> , 2019, 12, 130-139.	1.5	31
113	Facile generation of antibody heavy and light chain diversities for yeast surface display by Golden Gate Cloning. <i>Biological Chemistry</i> , 2019, 400, 383-393.	1.2	24
114	Nanomaterial-induced ferroptosis for cancer specific therapy. <i>Coordination Chemistry Reviews</i> , 2019, 382, 160-180.	9.5	122
115	Oriented immobilization to nanoparticles enhanced the therapeutic efficacy of antibody drugs. <i>Acta Biomaterialia</i> , 2019, 86, 373-380.	4.1	14
116	Rabbit models of human diseases for diagnostics and therapeutics development. <i>Developmental and Comparative Immunology</i> , 2019, 92, 99-104.	1.0	17
117	A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. <i>Methods</i> , 2019, 154, 38-50.	1.9	36
118	Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 213-226.	1.9	33
119	Structure, heterogeneity and developability assessment of therapeutic antibodies. <i>MAbs</i> , 2019, 11, 239-264.	2.6	186
120	Atomic Force Microscopy in Probing Tumor Physics for Nanomedicine. <i>IEEE Nanotechnology Magazine</i> , 2019, 18, 83-113.	1.1	24
121	Immune Effector Functions of Human IgG2 Antibodies against EGFR. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 75-88.	1.9	22
122	Protein drug delivery: current dosage form profile and formulation strategies. <i>Journal of Drug Targeting</i> , 2020, 28, 339-355.	2.1	29
123	Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 30-43.	1.6	8
124	Considerations for the Design of Antibody-Based Therapeutics. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 74-103.	1.6	146
125	NHP-immunome: A translational research-oriented database of non-human primate immune system proteins. <i>Cellular Immunology</i> , 2020, 347, 103999.	1.4	1
126	NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies. <i>MAbs</i> , 2020, 12, 1686319.	2.6	2



#	ARTICLE	IF	CITATIONS
127	IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47's SIRP's Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2020, 8, 120-130.	1.6	57
128	Magnetic bead-based semi-automated phage display panning strategy for the directed evolution of antibodies. <i>Methods in Enzymology</i> , 2020, 630, 159-178.	0.4	5
129	Cancer's Cell's Specific Drug Delivery by a Tumor's Homing CPP's Gossypol Conjugate Employing a Tracelessly Cleavable Linker. <i>Chemistry - A European Journal</i> , 2020, 26, 3010-3015.	1.7	22
130	Bispecific antibodies in cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 9-16.	3.3	59
131	HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7. <i>International Journal of Pharmaceutics</i> , 2020, 574, 118939.	2.6	14
132	Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 93-111.	21.5	190
133	Multifaceted antibodies development against synthetic's dystroglycan mucin glycopeptide as promising tools for dystroglycanopathies diagnostic. <i>Glycoconjugate Journal</i> , 2020, 37, 77-93.	1.4	4
134	Efficacy of the Antibody's Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 168-177.	1.9	19
135	Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies. <i>MAbs</i> , 2020, 12, 1692764.	2.6	27
136	Improved Physical Stability of an Antibody's Drug Conjugate Using Host's Guest Chemistry. <i>Bioconjugate Chemistry</i> , 2020, 31, 123-129.	1.8	6
137	Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3111-3122.	1.2	55
138	Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models. <i>MAbs</i> , 2020, 12, 1829337.	2.6	13
139	When liposomes met antibodies: Drug delivery and beyond. <i>Advanced Drug Delivery Reviews</i> , 2020, 154-155, 151-162.	6.6	51
140	Antibody Conjugate Assembly on Ultrasound-Confined Microcarrier Particles. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 6108-6116.	2.6	6
141	Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. <i>Nature Communications</i> , 2020, 11, 4974.	5.8	25
142	Guidelines To Predict Binding Poses of Antibody's Integrin Complexes. <i>ACS Omega</i> , 2020, 5, 16379-16385.	1.6	1
143	Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics's The Tale of HER2. <i>Antibodies</i> , 2020, 9, 32.	1.2	15
144	Passive immunotherapies targeting A $\beta$ 2 and tau in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 144, 105010.	2.1	81

#	ARTICLE	IF	CITATIONS
145	Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. <i>MAbs</i> , 2020, 12, 1792084.	2.6	7
146	Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. <i>Frontiers in Chemistry</i> , 2020, 8, 571.	1.8	143
147	Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering. <i>Antibodies</i> , 2020, 9, 63.	1.2	15
148	Dendritic Nanotheranostic for the Delivery of Infliximab: A Potential Carrier in Rheumatoid Arthritis Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9101.	1.8	6
149	Bringing the Heavy Chain to Light: Creating a Symmetric, Bivalent IgG-Like Bispecific. <i>Antibodies</i> , 2020, 9, 62.	1.2	3
150	Recent progress in the molecular imaging of therapeutic monoclonal antibodies. <i>Journal of Pharmaceutical Analysis</i> , 2020, 10, 397-413.	2.4	16
151	Computationally Designed Cyclic Peptides Derived from an Antibody Loop Increase Breadth of Binding for Influenza Variants. <i>Structure</i> , 2020, 28, 1114-1123.e4.	1.6	21
152	Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. <i>Cancers</i> , 2020, 12, 2175.	1.7	17
153	Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 1557.	2.2	45
154	A potent antagonist antibody targeting connexin hemichannels alleviates Clouston syndrome symptoms in mutant mice. <i>EBioMedicine</i> , 2020, 57, 102825.	2.7	20
155	Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2223.	1.7	18
156	Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-Fc $\gamma$ R-Deficient Human IL-15 Transgenic Mouse. <i>Frontiers in Immunology</i> , 2020, 11, 532684.	2.2	10
157	Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities. <i>Toxins</i> , 2020, 12, 658.	1.5	14
158	First clinical study of a pegylated diabody <sup>124</sup> I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. <i>Theranostics</i> , 2020, 10, 11404-11415.	4.6	13
159	Cross-species/cross-modality physiologically based pharmacokinetics for biologics: <sup>89</sup> Zr-labelled albumin-binding domain antibody GSK3128349 in humans. <i>MAbs</i> , 2020, 12, 1832861.	2.6	8
160	Injectables and Depots to Prolong Drug Action of Proteins and Peptides. <i>Pharmaceutics</i> , 2020, 12, 999.	2.0	32
161	Soluble ligands as drug targets. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 695-710.	21.5	63
162	Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 213.	7.1	387

#	ARTICLE	IF	CITATIONS
163	Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. <i>Frontiers in Immunology</i> , 2020, 11, 1986.	2.2	146
164	Precision medicine in clinical oncology: the journey from IgG antibody to IgE. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 282-289.	1.1	1
165	Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing. <i>PLoS ONE</i> , 2020, 15, e0232311.	1.1	16
166	Local environment effects on charged mutations for developing aggregation-resistant monoclonal antibodies. <i>Scientific Reports</i> , 2020, 10, 21191.	1.6	0
167	A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza. <i>Frontiers in Immunology</i> , 2020, 11, 606518.	2.2	2
168	The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. <i>Antibodies</i> , 2020, 9, 58.	1.2	41
169	The advent of de novo proteins for cancer immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2020, 56, 119-128.	2.8	15
170	The uniqueness of flow in probing the aggregation behavior of clinically relevant antibodies. <i>Engineering Reports</i> , 2020, 2, e12147.	0.9	5
171	Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer. <i>Advanced Science</i> , 2020, 7, 1903595.	5.6	22
172	Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. <i>Cellular and Molecular Immunology</i> , 2020, 17, 451-461.	4.8	83
173	Heterogeneous Drug Efficacy of an Antibody-Drug Conjugate Visualized Using Simultaneous Imaging of Its Delivery and Intracellular Damage in Living Tumor Tissues. <i>Translational Oncology</i> , 2020, 13, 100764.	1.7	1
174	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. <i>Cell</i> , 2020, 181, 1458-1463.	13.5	92
175	Simple Addition of Glycine in Trifluoroacetic Acid-Containing Mobile Phases Enhances the Sensitivity of Electrospray Ionization Mass Spectrometry for Biopharmaceutical Characterization. <i>Analytical Chemistry</i> , 2020, 92, 8691-8696.	3.2	8
176	Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1189-1211.	2.4	24
177	Isobaric Tandem Mass Tag Multiplexed Post-Translational Modification Quantitation of Biopharmaceuticals by Targeted High-Resolution Mass Spectrometry. <i>Analytical Chemistry</i> , 2020, 92, 9682-9690.	3.2	3
178	Aptamers as Versatile Molecular Tools for Antibody Production Monitoring and Quality Control. <i>Journal of the American Chemical Society</i> , 2020, 142, 12079-12086.	6.6	30
179	Efficient and selective antibody modification with functionalised divinyltriazines. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 4739-4743.	1.5	17
180	Vesicular antibodies for immunotherapy: The blooming intersection of nanotechnology and biotechnology. <i>Nano Today</i> , 2020, 34, 100896.	6.2	7

#	ARTICLE	IF	CITATIONS
181	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. <i>Pharmaceutics</i> , 2020, 12, 551.	2.0	9
183	Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats. <i>Current Medical Science</i> , 2020, 40, 28-34.	0.7	2
184	Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. <i>MAbs</i> , 2020, 12, 1739408.	2.6	27
185	DNA Origami-Enabled Engineering of Ligand-Drug Conjugates for Targeted Drug Delivery. <i>Small</i> , 2020, 16, e1904857.	5.2	58
186	Intein mediated high throughput screening for bispecific antibodies. <i>MAbs</i> , 2020, 12, 1731938.	2.6	23
187	Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors. <i>PLoS ONE</i> , 2020, 15, e0229206.	1.1	21
188	Protein-Polydimethylsiloxane Particles in Liquid Vial Monoclonal Antibody Formulations Containing Poloxamer 188. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2393-2404.	1.6	33
189	ImmunoPET: Concept, Design, and Applications. <i>Chemical Reviews</i> , 2020, 120, 3787-3851.	23.0	263
190	Construction of Bispecific Aptamer-Drug Conjugate by a Hybrid Chemical and Biological Approach. <i>Bioconjugate Chemistry</i> , 2020, 31, 1289-1294.	1.8	14
191	Tailoring translational strength using Kozak sequence variants improves bispecific antibody assembly and reduces product-related impurities in CHO cells. <i>Biotechnology and Bioengineering</i> , 2020, 117, 1946-1960.	1.7	16
192	Reproducible quantification of IgG uptake at endogenous and overexpressed FcRn levels at pH 7.4: Comparison of a wild type IgG and a stronger FcRn binding variant. <i>Journal of Immunological Methods</i> , 2020, 480, 112767.	0.6	0
193	Selection of a Full Agonist Combinatorial Antibody that Rescues Leptin Deficiency In Vivo. <i>Advanced Science</i> , 2020, 7, 2000818.	5.6	8
194	Engineering repeat proteins of the immune system. <i>Biopolymers</i> , 2020, 111, e23348.	1.2	1
195	Intracellular Delivery of Anti-SMC2 Antibodies against Cancer Stem Cells. <i>Pharmaceutics</i> , 2020, 12, 185.	2.0	16
196	Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. <i>Trends in Cancer</i> , 2020, 6, 130-146.	3.8	58
197	Site-specific Bioconjugation and Convergent Click Chemistry Enhances Antibody-Chromophore Conjugate Binding Efficiency. <i>Photochemistry and Photobiology</i> , 2020, 96, 596-603.	1.3	14
198	Monte Carlo simulations using PELE to identify a protein-protein inhibitor binding site and pose. <i>RSC Advances</i> , 2020, 10, 7058-7064.	1.7	7
199	Rapid Delivery of Nanobodies/VHHs into Living Cells via Expressing In Vitro-Transcribed mRNA. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 401-408.	1.8	18

#	ARTICLE	IF	CITATIONS
200	Classification of Trispanins: A Diverse Group of Proteins That Function in Membrane Synthesis and Transport Mechanisms. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 386.	1.8	0
201	Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates. <i>European Journal of Medicinal Chemistry</i> , 2020, 190, 112080.	2.6	15
202	Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 2.	1.0	5
203	30 Years of Biotherapeutics Development—What Have We Learned?. <i>Annual Review of Immunology</i> , 2020, 38, 249-287.	9.5	11
204	Generation and validation of structurally defined antibody-siRNA conjugates. <i>Nucleic Acids Research</i> , 2020, 48, 5281-5293.	6.5	26
205	Improved GPCR ligands from nanobody tethering. <i>Nature Communications</i> , 2020, 11, 2087.	5.8	42
206	Rational Design Principles of Attenuated Cationic Lytic Peptides for Intracellular Delivery of Biomacromolecules. <i>Molecular Pharmaceutics</i> , 2020, 17, 2175-2185.	2.3	15
207	Development of pepper vein banding virus chimeric virus-like particles for potential diagnostic and therapeutic applications. <i>Archives of Virology</i> , 2020, 165, 1163-1176.	0.9	6
208	Relationship of PEG-induced precipitation with protein-protein interactions and aggregation rates of high concentration mAb formulations at 5°C. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 151, 53-60.	2.0	13
209	Screening of new cell cycle suppressive compounds from marine-derived microorganisms in Chinese hamster ovary cells. <i>Journal of Bioscience and Bioengineering</i> , 2020, 130, 106-113.	1.1	2
210	The Biotechnology Sector: Therapeutics. , 2020, , 89-302.		1
211	Anti-HER2 Affibody-Conjugated Photosensitizer for Tumor Targeting Photodynamic Therapy. <i>Molecular Pharmaceutics</i> , 2020, 17, 1546-1557.	2.3	13
212	Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7764-7775.	3.3	54
213	Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. , 2020, 8, e000548.		13
214	The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1594-1601.	2.8	9
215	Heterogeneous Strategies to Eliminate Intracellular Bacterial Pathogens. <i>Frontiers in Microbiology</i> , 2020, 11, 563.	1.5	22
216	Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. <i>BioDrugs</i> , 2020, 34, 435-462.	2.2	24
217	Antibody-Drug Conjugates: Patient and Treatment Selection. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 105-114.	1.8	12

#	ARTICLE	IF	CITATIONS
218	Antibody-drug conjugates for the treatment of ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 875-887.	1.4	11
219	A photoactivatable antibody- <sup>65</sup> Chlorin e6 conjugate enabling singlet oxygen production for tumor-targeting photodynamic therapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 045003.	1.7	7
220	Molecularly Imprinted Polymer Nanoparticles: An Emerging Versatile Platform for Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 3858-3869.	7.2	113
221	Harnessing SLE Autoantibodies for Intracellular Delivery of Biologic Therapeutics. <i>Trends in Biotechnology</i> , 2021, 39, 298-310.	4.9	16
222	Driving CARs with alternative navigation tools – the potential of engineered binding scaffolds. <i>FEBS Journal</i> , 2021, 288, 2103-2118.	2.2	23
223	A hydrophobic interaction chromatography method suitable for quantitating individual monoclonal antibodies contained in co-formulated drug products. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 193, 113703.	1.4	6
224	Systematic Activity Maturation of a Single-Domain Antibody with Non-canonical Amino Acids through Chemical Mutagenesis. <i>Cell Chemical Biology</i> , 2021, 28, 70-77.e5.	2.5	15
225	Say no to drugs: Bioactive macromolecular therapeutics without conventional drugs. <i>Journal of Controlled Release</i> , 2021, 330, 1191-1207.	4.8	10
226	<i>Biotechnology and drugs.</i> , 2021, , 397-415.		2
227	A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFR <sup>β</sup> exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model. <i>International Journal of Pharmaceutics</i> , 2021, 592, 120037.	2.6	7
228	The Impact of Product and Process Related Critical Quality Attributes on Immunogenicity and Adverse Immunological Effects of Biotherapeutics. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1025-1041.	1.6	15
229	A general Fc engineering platform for the next generation of antibody therapeutics. <i>Theranostics</i> , 2021, 11, 1901-1917.	4.6	15
230	Human immunology and immunotherapy: main achievements and challenges. <i>Cellular and Molecular Immunology</i> , 2021, 18, 805-828.	4.8	96
231	Molecularly Imprinted Polymer Nanoparticles: An Emerging Versatile Platform for Cancer Therapy. <i>Angewandte Chemie</i> , 2021, 133, 3902-3913.	1.6	9
232	Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases. <i>Theranostics</i> , 2021, 11, 5430-5446.	4.6	18
233	Antibody Identification for Antigen Detection in Formalin-Fixed Paraffin-Embedded Tissue Using Phage Display and Na <sup>+</sup> Libraries. <i>Antibodies</i> , 2021, 10, 4.	1.2	5
234	Comparison of the pH- and thermally-induced fluctuations of a therapeutic antibody Fab fragment by molecular dynamics simulation. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2726-2741.	1.9	7
235	NECTIN4: A Novel Therapeutic Target for Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 976.	1.8	22

#	ARTICLE	IF	CITATIONS
236	Therapeutic antibody developmentâ€”Remington chapter. , 2021, , 437-462.		0
237	Protective antibodies against human parainfluenza virus type 3 infection. MAb, 2021, 13, 1912884.	2.6	13
238	Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential. , 2021, , 271-308.		0
239	Cancer Immunity. , 2021, , 129-146.		0
240	Chemistry in ADC Development. Drug Delivery System, 2021, 36, 28-39.	0.0	0
241	Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Computational and Structural Biotechnology Journal, 2021, 19, 2537-2548.	1.9	18
242	Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAb, 2021, 13, 1967714.	2.6	34
243	Fast Afucosylation Profiling of Glycoengineered Antibody Subunits by Middle-Up Mass Spectrometry. Methods in Molecular Biology, 2021, 2271, 73-83.	0.4	2
244	Preparation and functional evaluation of monoclonal antibodies targeting Hepatitis B Virus Polymerase. Virulence, 2021, 12, 188-194.	1.8	2
245	Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAb, 2021, 13, 1850395.	2.6	10
246	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.		0
247	Physical â€”strengthâ€” of the multiâ€”protein chain connecting immune cells: Does the weakest link limit antibody affinity maturation?. BioEssays, 2021, 43, 2000159.	1.2	5
248	Binding Proteins   Antibodies: Structure and Immune Effector Functions. , 2021, , 547-558.		1
249	The Current Landscape of Antibody-based Therapies in Solid Malignancies. Theranostics, 2021, 11, 1493-1512.	4.6	20
250	Chemical Diversification of Simple Synthetic Antibodies. ACS Chemical Biology, 2021, 16, 344-359.	1.6	28
251	Novel method for screening functional antibody with comprehensive analysis of its immunoliposome. Scientific Reports, 2021, 11, 4625.	1.6	4
252	Suppression of Electrostatic Mediated Antibody Liquidâ€”Liquid Phase Separation by Charged and Noncharged Preferentially Excluded Excipients. Molecular Pharmaceutics, 2021, 18, 1285-1292.	2.3	4
253	PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates. International Journal of Molecular Sciences, 2021, 22, 1540.	1.8	7

#	ARTICLE	IF	CITATIONS
254	Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing. <i>Nature Communications</i> , 2021, 12, 1277.	5.8	3
255	Unlocking the potential of antibody–drug conjugates for cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 327-344.	12.5	498
256	Synthetic Biology: Emerging Concepts to Design and Advance Adeno-Associated Viral Vectors for Gene Therapy. <i>Advanced Science</i> , 2021, 8, 2004018.	5.6	27
257	Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations. <i>Cancers</i> , 2021, 13, 669.	1.7	57
258	Microdroplet Ultrafast Reactions Speed Antibody Characterization. <i>Analytical Chemistry</i> , 2021, 93, 3997-4005.	3.2	32
259	Nano-Oncologics: A Tortoise Trail Reaching New Avenues. <i>Advanced Functional Materials</i> , 2021, 31, 2009860.	7.8	13
260	Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells. <i>Antibodies</i> , 2021, 10, 6.	1.2	10
261	Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. <i>Pharmaceutics</i> , 2021, 13, 422.	2.0	16
262	Importance of antibody isotypes in antitumor immunity by monocytes and complement using human-immune tumor models. <i>European Journal of Immunology</i> , 2021, 51, 1218-1233.	1.6	5
263	Process and operations strategies to enable global access to antibody therapies. <i>Biotechnology Progress</i> , 2021, 37, e3139.	1.3	18
264	An in vivo method for diversifying the functions of therapeutic antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	3
265	In Translation: FcRn across the Therapeutic Spectrum. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3048.	1.8	21
266	An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation. <i>Biochemistry</i> , 2021, 60, 1080-1087.	1.2	5
267	Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. <i>Antibodies</i> , 2021, 10, 13.	1.2	21
268	Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 151-165.	4.0	94
269	Genetic rearrangement during site specific integration event facilitates cell line development of a bispecific molecule. <i>Biotechnology Progress</i> , 2021, 37, e3158.	1.3	5
270	Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 668207.	2.2	57
271	Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.120.259036.	2.8	3



#	ARTICLE	IF	CITATIONS
272	Calibration for quantitative Fc-glycosylation analysis of therapeutic IgG1-type monoclonal antibodies by using glycopeptide standards. <i>Analytica Chimica Acta</i> , 2021, 1154, 338306.	2.6	1
274	Biomaterials-Based Delivery of Therapeutic Antibodies for Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002139.	3.9	21
275	Investigating native capillary zone electrophoresis-mass spectrometry on a high-end quadrupole-time-of-flight mass spectrometer for the characterization of monoclonal antibodies. <i>International Journal of Mass Spectrometry</i> , 2021, 462, 116541.	0.7	24
276	A Computational Investigation of In Vivo Cytosolic Protein Delivery for Cancer Therapy. <i>Pharmaceutics</i> , 2021, 13, 562.	2.0	5
277	The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control. <i>ACS Central Science</i> , 2021, 7, 724-738.	5.3	41
278	The triad of nanotechnology, cell signalling, and scaffold implantation for the successful repair of damaged organs: An overview on soft-tissue engineering. <i>Journal of Controlled Release</i> , 2021, 332, 460-492.	4.8	50
279	An Automated Multicycle Immunoaffinity Enrichment Approach Developed for Sensitive Mouse IgG1 Antibody Drug Analysis in Mouse Plasma Using LC/MS/MS. <i>Analytical Chemistry</i> , 2021, 93, 6348-6354.	3.2	3
280	Anti-M $\beta$ gallic hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival. <i>International Journal of Oncology</i> , 2021, 59, .	1.4	3
282	Assessment of Antibody Stability in a Novel Protein-Free Serum Model. <i>Pharmaceutics</i> , 2021, 13, 774.	2.0	7
283	Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease. <i>International Journal of Pharmaceutics</i> , 2021, 600, 120461.	2.6	19
284	Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 680834.	1.3	32
285	A Hybrid In Silico and Tumor-on-a-Chip Approach to Model Targeted Protein Behavior in 3D Microenvironments. <i>Cancers</i> , 2021, 13, 2461.	1.7	8
286	Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. <i>Nature Communications</i> , 2021, 12, 3790.	5.8	29
288	Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions. <i>Cancer Science</i> , 2021, 112, 3029-3040.	1.7	11
289	FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6475.	1.8	9
290	Progress in Gynecologic Cancers with Antibody Drug Conjugates. <i>Current Oncology Reports</i> , 2021, 23, 89.	1.8	3
291	High-throughput developability assays enable library-scale identification of producible protein scaffold variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	18
292	Mass Spectrometry-Based <i>de Novo</i> Sequencing of Monoclonal Antibodies Using Multiple Proteases and a Dual Fragmentation Scheme. <i>Journal of Proteome Research</i> , 2021, 20, 3559-3566.	1.8	27

#	ARTICLE	IF	CITATIONS
293	Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. , 2021, 9, e002582.		14
295	Cytosolic Protein Delivery for Intracellular Antigen Targeting Using Supercharged Polypeptide Delivery Platform. Nano Letters, 2021, 21, 6022-6030.	4.5	25
297	Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues. Pharmaceuticals, 2021, 14, 672.	1.7	10
298	Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM. Journal of Nuclear Medicine, 2022, 63, 629-636.	2.8	5
299	Engineered protein-small molecule conjugates empower selective enzyme inhibition. Cell Chemical Biology, 2022, 29, 328-338.e4.	2.5	8
300	Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. Drug Discovery Today, 2021, 26, 1980-1990.	3.2	3
301	Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery. Advanced Drug Delivery Reviews, 2021, 175, 113778.	6.6	13
302	A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer. Cells, 2021, 10, 2218.	1.8	7
303	Plectin in Cancer: From Biomarker to Therapeutic Target. Cells, 2021, 10, 2246.	1.8	17
304	Antibody engineering and its therapeutic applications. International Reviews of Immunology, 2023, 42, 156-183.	1.5	5
305	Effects of Secondary Package on Freeze-Dried Biopharmaceutical Formulation Stability During Dropping. Journal of Pharmaceutical Sciences, 2021, 110, 2916-2924.	1.6	3
306	Strategies for targeting undruggable targets. Expert Opinion on Drug Discovery, 2022, 17, 55-69.	2.5	34
307	Daratumumab Immunopolymersomeâ€Enabled Safe and CD38â€Targeted Chemotherapy and Depletion of Multiple Myeloma. Advanced Materials, 2021, 33, e2007787.	11.1	25
308	Recombinant immunotoxins development for HER2-based targeted cancer therapies. Cancer Cell International, 2021, 21, 470.	1.8	16
309	Progress and challenges in mass spectrometry-based analysis of antibody repertoires. Trends in Biotechnology, 2022, 40, 463-481.	4.9	23
310	Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Advanced Materials, 2021, 33, e2103114.	11.1	6
311	Integration and digitalization in the manufacturing of therapeutic proteins. Chemical Engineering Science, 2022, 248, 117159.	1.9	32
312	The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. Blood Advances, 2021, 5, 3807-3820.	2.5	9

#	ARTICLE	IF	CITATIONS
313	Analytical Challenges Assessing Protein Aggregation and Fragmentation Under Physiologic Conditions. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 3103-3110.	1.6	10
314	Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics. <i>Advanced Science</i> , 2021, 8, e2100460.	5.6	34
315	Success stories of AI in drug discovery - where do things stand?. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 79-92.	2.5	21
316	A new humanized antibody is effective against pathogenic fungi in vitro. <i>Scientific Reports</i> , 2021, 11, 19500.	1.6	13
317	Production of monoclonal shark-derived immunoglobulin new antigen receptor antibodies using Chinese hamster ovary cell expression system. <i>Journal of Bioscience and Bioengineering</i> , 2021, 132, 302-309.	1.1	2
319	Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P. <i>Journal of Biological Chemistry</i> , 2021, 297, 101136.	1.6	0
320	RNA aptamers for AMPA receptors. <i>Neuropharmacology</i> , 2021, 199, 108761.	2.0	5
321	Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn <i>in vitro</i> and <i>in vivo</i> . <i>MAbs</i> , 2021, 13, 1893888.	2.6	16
322	Homing Peptides for Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 29-48.	0.8	21
324	Development of an In Vitro Potency Assay System for Quality Control of Anti- Human Epidermal Growth Factor Receptor 2 Antibody Admixtures. , 0, , .		0
325	Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting. <i>Current Cancer Drug Targets</i> , 2021, 21, 70-79.	0.8	11
326	Homogeneous Antibody-Drug Conjugates via Glycoengineering. <i>Methods in Molecular Biology</i> , 2019, 2033, 221-238.	0.4	4
327	Engineering Dual Variable Domains for the Generation of Site-Specific Antibody-Drug Conjugates. <i>Methods in Molecular Biology</i> , 2019, 2033, 39-52.	0.4	8
328	Analysis of ADCs by Native Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2020, 2078, 197-211.	0.4	2
329	Application of Fluorescence in Studying Therapeutic Enzymes. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1148, 105-114.	0.8	3
330	Non-invasive delivery of biological macromolecular drugs into the skin by iontophoresis and its application to psoriasis treatment. <i>Journal of Controlled Release</i> , 2020, 323, 323-332.	4.8	39
331	The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. , 2020, 212, 107574.		19
332	The Business of Healthcare Innovation. , 2020, , .		2

#	ARTICLE	IF	CITATIONS
333	Development of a universal method for the measurement of binding affinities of antibody drugs towards a living cell based on AFM force spectroscopy. <i>Analytical Methods</i> , 2020, 12, 2922-2927.	1.3	8
338	Recent Progress in Capturing and Neutralizing Inflammatory Cytokines. <i>CCS Chemistry</i> , 2020, 2, 376-389.	4.6	16
339	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
340	Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. <i>RSC Chemical Biology</i> , 2022, 3, 140-169.	2.0	5
341	Computational maturation of a single-domain antibody against A $\beta$ 242 aggregation. <i>Chemical Science</i> , 2021, 12, 13940-13948.	3.7	4
342	Single-domain antibody screening by <i>is</i> <i>i</i> PLA-seq. <i>Life Science Alliance</i> , 2022, 5, e202101115.	1.3	1
344	The tumour neovasculature-homing dimeric peptide GX1 demonstrates antiangiogenic activity in the retinal neovasculature. <i>European Journal of Pharmacology</i> , 2021, 912, 174574.	1.7	1
349	Chapter 13: Formulation Development for Biologics Utilizing Lab Automation and In Vivo Performance Models. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2020, , 299-341.	0.2	0
351	Specific Inhibitor of Placental Alkaline Phosphatase Isolated from a DNA-Encoded Chemical Library Targets Tumor of the Female Reproductive Tract. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15799-15809.	2.9	8
352	Attempts to synthesize homogeneous glycan-conjugated antibody-drug conjugates. <i>Translational and Regulatory Sciences</i> , 2020, 2, 84-89.	0.2	0
353	Macromolecules and Antibody-Based Drugs. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 485-530.	0.8	3
354	Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 21, 162-186.	0.9	2
356	Rapid identification of anti-idiotypic mAbs with high affinity and diverse epitopes by rabbit single B-cell sorting-culture and cloning technology. <i>PLoS ONE</i> , 2020, 15, e0244158.	1.1	11
358	Chapter 14. Classes, Modes of Action and Selection of New Modalities in Drug Discovery. <i>RSC Drug Discovery Series</i> , 2020, , 277-316.	0.2	0
360	Single B cell technologies for monoclonal antibody discovery. <i>Trends in Immunology</i> , 2021, 42, 1143-1158.	2.9	63
361	Epitope screening using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS): An accelerated workflow for evaluation of lead monoclonal antibodies. <i>Biotechnology Journal</i> , 2022, 17, e2100358.	1.8	14
362	Stress-dependent Flexibility of a Full-length Human Monoclonal Antibody: Insights from Molecular Dynamics to Support Biopharmaceutical Development. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 628-637.	1.6	7
364	Antibody DDS therapeutics against cancer, inflammatory autoimmune and infectious disease. <i>Drug Delivery System</i> , 2020, 35, 356-366.	0.0	0

#	ARTICLE	IF	CITATIONS
365	Molekular zielgerichtete Therapie. , 2022, , 47-52.		0
367	Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. Small Methods, 2022, 6, 2100966.	4.6	1
368	Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent. Frontiers in Pharmacology, 2021, 12, 748936.	1.6	3
369	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. Journal of Virology, 2022, 96, JVI0155121.	1.5	18
370	An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer. Journal of Controlled Release, 2021, 340, 331-341.	4.8	19
371	Rapid structural discrimination of IgG antibodies by multicharge-state collision-induced unfolding. RSC Advances, 2021, 11, 36502-36510.	1.7	1
372	Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. Oncoimmunology, 2021, 10, .	2.1	14
373	Probing protein aggregation at buried interfaces: distinguishing between adsorbed protein monomers, dimers, and a monomer-dimer mixture <i>in situ</i> . Chemical Science, 2022, 13, 975-984.	3.7	13
374	Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics. Bioorganic Chemistry, 2022, 119, 105563.	2.0	12
375	Antibodies targeting enzyme inhibition as potential tools for research and drug development. Biomolecular Concepts, 2021, 12, 215-232.	1.0	3
376	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody <i>in vivo</i> efficacy. , 2022, 10, e003766.		15
377	Epigenetic comparison of CHO hosts and clones reveals divergent methylation and transcription patterns across lineages. Biotechnology and Bioengineering, 2022, 119, 1062-1076.	1.7	6
378	Patient Centricity Driving Formulation Innovation: Improvements in Patient Care Facilitated by Novel Therapeutics and Drug Delivery Technologies. Annual Review of Pharmacology and Toxicology, 2022, 62, 341-363.	4.2	6
379	Partial Magneto-Endosomalysis for Cytosolic Delivery of Antibodies. Bioconjugate Chemistry, 2022, 33, 363-368.	1.8	3
380	ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation. Bioinformatics, 2022, 38, 1877-1880.	1.8	78
381	Prevention of Fetal/Neonatal Alloimmune Thrombocytopenia in Mice: Biochemical and Cell Biological Characterization of Isoforms of a Human Monoclonal Antibody. ImmunoHorizons, 2022, 6, 90-103.	0.8	2
382	CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies. MAbs, 2022, 14, 2024118.	2.6	4
383	Self-Assembly of Oriented Antibody-Decorated Metal-Organic Framework Nanocrystals for Active-Targeting Applications. Advanced Materials, 2022, 34, e2106607.	11.1	23

#	ARTICLE	IF	CITATIONS
384	Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. <i>MABs</i> , 2022, 14, 2020082.	2.6	35
385	Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. <i>IScience</i> , 2022, 25, 103746.	1.9	23
386	Deep mutational scanning for therapeutic antibody engineering. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 123-135.	4.0	18
387	Tricyclic cell-penetrating peptides for efficient delivery of functional antibodies into cancer cells. <i>Nature Chemistry</i> , 2022, 14, 284-293.	6.6	65
388	Emerging new therapeutic antibody derivatives for cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 39.	7.1	158
389	Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. <i>Pharmaceutics</i> , 2022, 14, 396.	2.0	48
390	Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. <i>Oncolmmunology</i> , 2022, 11, 2039432.	2.1	14
391	Progress on Optical Fiber Biochemical Sensors Based on Graphene. <i>Micromachines</i> , 2022, 13, 348.	1.4	13
392	Impact of charge patches on tumor disposition and biodistribution of therapeutic antibodies. <i>AAPS Open</i> , 2022, 8, .	0.4	3
393	Landscape of surfaceome and endocytome in human glioma is divergent and depends on cellular spatial organization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
394	Storable protection-free BGL reagents possessing a bioorthogonal functional group at apex. <i>Tetrahedron</i> , 2022, 110, 132690.	1.0	1
395	Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model. <i>Scientific Reports</i> , 2022, 12, 3530.	1.6	5
396	Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. <i>MABs</i> , 2022, 14, 2008790.	2.6	51
397	Freeze-Dried Monoclonal Antibody Formulations are Unexpectedly More Prone to Degradation Than Liquid Formulations Under Shaking Stress. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2134-2138.	1.6	3
398	Combating Cancer Stem-Like Cell-Derived Resistance to Anticancer Protein by Liposome-Mediated Acclimatization Strategy. <i>Nano Letters</i> , 2022, 22, 2419-2428.	4.5	12
399	SSH2.0: A Better Tool for Predicting the Hydrophobic Interaction Risk of Monoclonal Antibody. <i>Frontiers in Genetics</i> , 2022, 13, 842127.	1.1	6
401	In silico proof of principle of machine learning-based antibody design at unconstrained scale. <i>MABs</i> , 2022, 14, 2031482.	2.6	40
402	Current Progress and Prospects in Rabbit Cloning. <i>Cellular Reprogramming</i> , 2022, 24, 63-70.	0.5	1

#	ARTICLE	IF	CITATIONS
403	Why medicines work. , 2022, 238, 108175.		1
404	Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof. <i>Pharmaceutics</i> , 2022, 14, 28.	2.0	17
405	Charting the tumor antigen maps drawn by single-cell genomics. <i>Cancer Cell</i> , 2021, 39, 1553-1557.	7.7	9
406	Not your usual drug-drug interactions: Monoclonal antibody-based therapeutics may interact with antiseizure medications. <i>Epilepsia</i> , 2022, 63, 271-289.	2.6	6
407	The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. <i>Nature Cancer</i> , 2021, 2, 1406-1422.	5.7	33
408	DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo. <i>Nature Communications</i> , 2021, 12, 7344.	5.8	9
409	Mapeamento Tecnol3gico dos Anticorpos Conjugados no Tratamento das Doen3as Cr3nicas: C3ncer. <i>Cadernos De Prospec33o</i> , 2020, 13, 120.	0.0	0
410	Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 149-171.	0.5	3
411	G Protein-coupled Receptor (GPCR) Reconstitution and Labeling for Solution Nuclear Magnetic Resonance (NMR) Studies of the Structural Basis of Transmembrane Signaling. <i>Molecules</i> , 2022, 27, 2658.	1.7	8
426	Impact of Poloxamer 188 Material Attributes on Proteinaceous Visible Particle Formation in Liquid Monoclonal Antibody Formulations. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2191-2200.	1.6	8
427	Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 131.	7.1	190
428	Engineering Binders with Exceptional Selectivity. <i>Methods in Molecular Biology</i> , 2022, 2491, 143-154.	0.4	3
429	Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties. <i>MABs</i> , 2022, 14, 2056944.	2.6	13
430	AbSE Workflow: Rapid Identification of the Coding Sequence and Linear Epitope of the Monoclonal Antibody at the Single-cell Level. <i>ACS Synthetic Biology</i> , 2022, 11, 1856-1864.	1.9	0
431	Therapeutic bispecific antibodies against intracellular tumor antigens. <i>Cancer Letters</i> , 2022, 538, 215699.	3.2	12
432	Monitoring multiple quality attributes of a complex Fc-fusion protein during cell culture production processes by mD-LC-MS peptide mapping. <i>Talanta</i> , 2022, 246, 123519.	2.9	7
434	Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer. <i>Nature Cancer</i> , 2022, 3, 565-580.	5.7	18
436	A Traceless Site-Specific Conjugation on Native Antibodies Enables Efficient One-Step Payload Assembly. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	16

#	ARTICLE	IF	CITATIONS
437	A Traceless Site-Specific Conjugation on Native Antibodies Enables Efficient One-Step Payload Assembly. <i>Angewandte Chemie</i> , 0, , .	1.6	0
438	Expression of mammalian proteins for diagnostics and therapeutics: a review. <i>Molecular Biology Reports</i> , 2022, 49, 10593-10608.	1.0	5
439	Effects of sidechain isomerism on polymer-based non-covalent protein delivery. <i>Chemical Communications</i> , 0, , .	2.2	0
440	Crystallographic mining of ASK1 regulators to unravel the intricate PPI interfaces for the discovery of small molecule. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3734-3754.	1.9	5
441	Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
443	Avidity in antibody effector functions and biotherapeutic drug design. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 715-735.	21.5	65
444	Designing antibodies as therapeutics. <i>Cell</i> , 2022, 185, 2789-2805.	13.5	65
445	Cellular Therapy Using Epitope-Imprinted Composite Nanoparticles to Remove $\beta$ -Synuclein from an In Vitro Model. <i>Cells</i> , 2022, 11, 2584.	1.8	4
446	Characterization of a Nanobody-Epitope Tag Interaction and Its Application for Receptor Engineering. <i>ACS Chemical Biology</i> , 2022, 17, 2296-2303.	1.6	10
447	Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. <i>Communications Biology</i> , 2022, 5, .	2.0	5
448	Effective blocking of neuropilin-1 activity using oligoclonal nanobodies targeting different epitopes. <i>Preparative Biochemistry and Biotechnology</i> , 2023, 53, 523-531.	1.0	1
449	Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	15
450	Triple negative breast cancer: approved treatment options and their mechanisms of action. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3701-3719.	1.2	13
451	A Hoechst Reporter Enables Visualization of Drug Engagement <i>In Vitro</i> and <i>In Vivo</i> : Toward Safe and Effective Nanodrug Delivery. <i>ACS Nano</i> , 2022, 16, 12290-12304.	7.3	9
452	Potential of antibody-drug conjugates (ADCs) for cancer therapy. <i>Cancer Cell International</i> , 2022, 22, .	1.8	36
453	Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	4
454	Extending the performance of FcRn and Fc $\gamma$ RIIIa affinity liquid chromatography for protein biopharmaceuticals. <i>Journal of Chromatography A</i> , 2022, 1682, 463518.	1.8	3
455	Rapamycin-encapsulated costimulatory ICOS/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment. <i>Biomaterials</i> , 2022, 289, 121766.	5.7	5



#	ARTICLE	IF	CITATIONS
456	Development and validation of a method for airborne monoclonal antibodies to quantify workplace exposure. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 221, 115046.	1.4	0
457	Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products. <i>Current Opinion in Biotechnology</i> , 2022, 78, 102798.	3.3	14
458	Target-triggered catalytic hairpin assembly activation of CRISPR/Cas12a for amplified detection of therapeutic monoclonal antibody. <i>Sensors and Actuators B: Chemical</i> , 2022, 372, 132578.	4.0	2
459	Peptide mimotopes to emulate carbohydrates. <i>Chemical Society Reviews</i> , 2022, 51, 8160-8173.	18.7	5
460	Drug targets and drug-target molecules. , 2022, , 97-149.		0
461	Antibody interfaces revealed through structural mining. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4952-4968.	1.9	3
462	Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
464	Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR. <i>Biochemistry</i> , 2022, 61, 2049-2062.	1.2	1
465	Computational Studies on Antibody Drug Conjugates (ADCs) for Precision Oncology. <i>ChemistrySelect</i> , 2022, 7, .	0.7	1
466	Recent Development of Photofunctional Transition Metal- <sup>II</sup> Peptide Conjugates for Bioimaging and Therapeutic Applications. <i>European Journal of Inorganic Chemistry</i> , 0, , .	1.0	2
467	Site-Selective Lysine Acetylation of Human Immunoglobulin G for Immunoliposomes and Bispecific Antibody Complexes. <i>Journal of the American Chemical Society</i> , 2022, 144, 18494-18503.	6.6	16
468	PEGylation of anti-MerTK Antibody Modulates Ocular Biodistribution. <i>Bioconjugate Chemistry</i> , 2022, 33, 1837-1851.	1.8	1
469	Targeting cancer stem cells with polymer nanoparticles for gastrointestinal cancer treatment. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	11
470	Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. <i>Cancer Discovery</i> , 2023, 13, 132-145.	7.7	19
471	Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
472	Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood-Brain Barrier of Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> . 2023. 384. 197-204.	1.3	2
473	Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. <i>Trends in Immunology</i> , 2022, 43, 932-946.	2.9	22
474	Impacts of fast production of afucosylated antibodies and Fc mutants in ExpiCHO-S <sup>™</sup> for enhancing FcγRIIIa binding and NK cell activation. <i>Journal of Biotechnology</i> , 2022, 360, 79-91.	1.9	1

#	ARTICLE	IF	CITATIONS
475	CD3â€¢Tâ€¢cellâ€¢engager (TCE) therapies to overcome solid tumors: Beyond BiTEs. , 2022, 1, .		1
476	Assessing and Engineering Antibody Stability Using Experimental and Computational Methods. <i>Methods in Molecular Biology</i> , 2023, , 165-197.	0.4	0
477	Optimizing Antibodyâ€¢Antigen Binding Affinities with the ADAPT Platform. <i>Methods in Molecular Biology</i> , 2023, , 361-374.	0.4	1
478	Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma. <i>Pharmaceutics</i> , 2022, 14, 2494.	2.0	0
480	Traceless pH-Sensitive Antibody Conjugation Inspired by Citraconic Anhydride. <i>Biomacromolecules</i> , 2022, 23, 5322-5329.	2.6	1
481	Role of GPR56 in platelet activation and arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 0, , .	1.8	0
482	Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. <i>Science China Life Sciences</i> , 2023, 66, 658-678.	2.3	3
483	Automated Hydrophobic Interaction Chromatography Screening Combined with <i>In Silico</i> Optimization as a Framework for Nondenaturing Analysis and Purification of Biopharmaceuticals. <i>Analytical Chemistry</i> , 2022, 94, 17131-17141.	3.2	5
486	Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins. <i>Molecules</i> , 2023, 28, 917.	1.7	12
487	Payload diversification: a key step in the development of antibodyâ€¢drug conjugates. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	42
488	CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. <i>Cancer Discovery</i> , 2023, 13, 552-569.	7.7	19
489	Rapid Characterization of Antibodies via Automated Flow Injection Coupled with Online Microdroplet Reactions and Native-pH Mass Spectrometry. <i>Analytical Chemistry</i> , 2023, 95, 3340-3348.	3.2	5
490	Vesicular Antibodies: Shedding Light on Antibody Therapeutics with Cell Membrane Nanotechnology. <i>Advanced Materials</i> , 2023, 35, .	11.1	8
491	Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
492	Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses. <i>Chemical Society Reviews</i> , 2023, 52, 2790-2832.	18.7	28
493	A coumarin-based small molecular fluorescent probe for detection of the freshness of meat and shrimp. <i>Journal of Food Composition and Analysis</i> , 2023, 118, 105231.	1.9	3
494	Nanobody Loop Mimetics Enhance Son of Sevenless 1â€¢Catalyzed Nucleotide Exchange on RAS**. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	1
495	Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy. <i>Cancers</i> , 2023, 15, 1015.	1.7	2

#	ARTICLE	IF	CITATIONS
496	Nanobodies: Robust miniprotein binders in biomedicine. <i>Advanced Drug Delivery Reviews</i> , 2023, 195, 114726.	6.6	7
497	Online Collision-Induced Unfolding of Therapeutic Monoclonal Antibody Glyco-Variants through Direct Hyphenation of Cation Exchange Chromatography with Native Ion Mobilityâ€“Mass Spectrometry. <i>Analytical Chemistry</i> , 2023, 95, 3932-3939.	3.2	5
498	Conjugation site characterization of antibodyâ€“drug conjugates using electron-transfer/higher-energy collision dissociation (ETHcD). <i>Analytica Chimica Acta</i> , 2023, 1251, 340978.	2.6	2
499	Oral Delivery of Therapeutic Antibodies with a Transmucosal Polymeric Carrier. <i>ACS Nano</i> , 2023, 17, 4373-4386.	7.3	16
500	Characterization of endogenous Kv1.3 channel isoforms in T cells. <i>Journal of Cellular Physiology</i> , 0, , .	2.0	1
501	Targeting Ras-binding domain of ELMO1 by computational nanobody design. <i>Communications Biology</i> , 2023, 6, .	2.0	3
502	Targeting cerebral diseases with enhanced delivery of therapeutic proteins across the blood-brain barrier. <i>Expert Opinion on Drug Delivery</i> , 2023, 20, 1681-1698.	2.4	1
503	Rabbit derived VL single-domains as promising scaffolds to generate antibodyâ€“drug conjugates. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
504	A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2â€“Bispecific Antibody for Combination Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 2686-2701.	3.2	4
505	Application of a Novel Aptamer Beacon for Rapid Detection of IgG1 Antibody Drugs. <i>Applied Biochemistry and Biotechnology</i> , 0, , .	1.4	1
506	Automated optimisation of solubility and conformational stability of antibodies and proteins. <i>Nature Communications</i> , 2023, 14, .	5.8	5
507	Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targets. <i>Journal of Biological Chemistry</i> , 2023, 299, 104685.	1.6	2
508	Bioconjugated materials: Preparation, characterization and therapeutic applications. <i>Comprehensive Analytical Chemistry</i> , 2023, , .	0.7	0
509	Enhanced Thermal Stability and Reduced Aggregation in an Antibody Fab Fragment at Elevated Concentrations. <i>Molecular Pharmaceutics</i> , 2023, 20, 2650-2661.	2.3	2
510	AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains. <i>Antibody Therapeutics</i> , 2023, 6, 147-156.	1.2	2
511	Nanobody Loop Mimetics Enhance Son of Sevenless 1â€“Catalyzed Nucleotide Exchange on RAS**. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	0
512	Application of Antibody Fragments in ADCs. , 2023, , 55-68.		0
518	Computational Methods in Natural Products-Based Drug Discovery. , 2023, , 99-121.		0

#	ARTICLE	IF	CITATIONS
529	The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics. Chemical Reviews, 2023, 123, 7782-7853.	23.0	13
532	Identification of New Antibodies Targeting Tumor Cell Surface Antigens by Phage Display. Methods in Molecular Biology, 2023, , 61-82.	0.4	1
539	Site-specific drug delivery utilizing monoclonal antibodies. , 2023, , 649-681.		0
541	Small-Molecule Inhibitors of Protein-Protein Interactions as Therapeutics. , 2023, , 343-428.		0
543	Single B-cell sequencing in monoclonal antibody discovery. , 2024, , 73-95.		0
548	Nanoconjugate formulations for enhanced drug delivery. , 2023, , 441-491.		1
551	Deep Mining of Complex Antibody Phage Pools. Methods in Molecular Biology, 2023, , 419-431.	0.4	0
559	T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature Reviews Drug Discovery, 2023, 22, 996-1017.	21.5	7
560	Organ-on-a-chip models for development of cancer immunotherapies. Cancer Immunology, Immunotherapy, 2023, 72, 3971-3983.	2.0	0